StatPearls, LLC

  • Aging, Premature
  • Carcinoma, Squamous Cell
  • Cataract
  • Osteosarcoma
  • Rothmund-Thomson Syndrome

Poikiloderma Congenitale

Congenital poikiloderma, or Rothmund-Thomson syndrome (RTS), is a rare genodermatosis with autosomal recessive inheritance. It is characterized by early-onset facial poikiloderma and associated with clinical features, including short stature, sparse scalp hair, absent or sparse eyelashes or eyebrows, juvenile cataracts, skeletal abnormalities, premature aging, and susceptibility to osteosarcoma. There are 2 types of congenital poikiloderma. Type 1 is characterized by rapidly progressive, bilateral, juvenile cataracts. In contrast, type 2 is characterized by congenital bone abnormalities and an increased risk of osteosarcoma in childhood and squamous cell carcinoma at an older age. This activity reviews the presentation, evaluation, and management of congenital poikiloderma and stresses the role of an interprofessional team approach to the care of affected patients.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 1 creditAMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 creditPharmacyUp to 1 credit

MOC types

ABS — Accredited CMEUp to 1 pointABPATH — Lifelong LearningUp to 1 pointABTS — Accredited CMEUp to 1 pointABS — Self-AssessmentUp to 1 pointABP — Lifelong Learning and Self-AssessmentUp to 1 pointABOHNS — Self-AssessmentUp to 1 pointABTS — Self-AssessmentUp to 1 point

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Cross-Specialty

Relevant across 8 specialties.

Pricing

Fee varies

This provider typically $49–98

See fees on statpearls.com

Listed by the provider

  • Article / monograph / reference
  • Credit · Up to 1 credit
  • MOC · Up to 1 point
  • Fee varies · this provider typically $49–98
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 1, 2029 3 years left